Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.

Abstract:

:We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 genes performed in 330 patients included in this trial, 163 patients being treated with lomustine in combination with idarubicin and cytarabine and 167 without lomustine, identified 1088 mutations with an average of 3.3 mutations per patient. NPM1, FLT3, and DNMT3A were the most frequently mutated genes. A putative therapeutic target was identified in 178 patients (54%). Among five molecular classifications analyzed, the ELN2017 risk classification has the stronger association with the clinical evolution. Patients not treated with lomustine have an expected survival prognosis in agreement with this classification regarding the overall and event-free survivals. In strong contrast, lomustine erased the ELN2017 classification prognosis. The benefit of lomustine in nonadverse chromosomal aberrations was restricted to patients with RUNX1, ASXL1, TP53, and FLT3-ITDhigh/NPM1WT mutations in contrast to the intermediate and favorable ELN2017 patients. This post-hoc analysis identified a subgroup of fit elderly AML patients with intermediate cytogenetics and molecular markers who may benefit from lomustine addition to intensive chemotherapy.

journal_name

Leukemia

journal_title

Leukemia

authors

Largeaud L,Cornillet-Lefebvre P,Hamel JF,Dumas PY,Prade N,Dufrechou S,Plenecassagnes J,Luquet I,Blanchet O,Banos A,Béné MC,Bernard M,Bertoli S,Bonmati C,Fornecker LM,Guièze R,Haddaoui L,Hunault M,Ianotto JC,Jourdan

doi

10.1038/s41375-020-01031-1

subject

Has Abstract

pub_date

2020-09-18 00:00:00

eissn

0887-6924

issn

1476-5551

pii

10.1038/s41375-020-01031-1

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia.

    abstract::In cell and animal models, telomere erosion promotes chromosomal instability via breakage-fusion-bridge cycles, contributing to the early stages of tumorigenesis. However, evidence involving short telomeres in cancer development in humans is scarce, epidemiological and indirect. Here we directly implicate telomere sho...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.272

    authors: Calado RT,Cooper JN,Padilla-Nash HM,Sloand EM,Wu CO,Scheinberg P,Ried T,Young NS

    更新日期:2012-04-01 00:00:00

  • Lack of evidence for abnormal autocrine or paracrine mechanisms underlying the uncontrolled proliferation of primitive chronic myeloid leukemia progenitor cells.

    abstract::Previous studies have revealed a consistent defect in the cycling behavior of primitive neoplastic progenitor cells in patients with Philadelphia chromosome (Ph1)-positive chronic myeloid leukemia (CML). This is manifested both in vivo and in long-term cultures of CML cells as an increased rate of turnover amongst Ph1...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Otsuka T,Eaves CJ,Humphries RK,Hogge DE,Eaves AC

    更新日期:1991-10-01 00:00:00

  • A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.

    abstract::Ligation of CD40 on chronic lymphocytic leukemia (CLL) cells induces phenotypic and biochemical changes that facilitate CLL cell-T cell interactions and enhances the sensitivity of CLL cells to clearance by adaptive and innate immune-effector mechanisms. CLL cells can be transduced to express CD40 ligand (CD154) using...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.191

    authors: Wierda WG,Castro JE,Aguillon R,Sampath D,Jalayer A,McMannis J,Prussak CE,Keating M,Kipps TJ

    更新日期:2010-11-01 00:00:00

  • Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation.

    abstract::HOX homeobox proteins are key oncogenic drivers in hematopoietic malignancies. Here we demonstrate that HOXA1, HOXA6 and predominantly HOXA9 are able to induce the production of insulin-like growth factor 1 (Igf1). In chromatin immunoprecipitations, HOXA9 bound directly to the putative promoter and a DNase-hypersensit...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.287

    authors: Steger J,Füller E,Garcia-Cuellar MP,Hetzner K,Slany RK

    更新日期:2015-04-01 00:00:00

  • Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.

    abstract::An antisense oligodeoxynucleotide (ODN) complementary to the first six codons of the Bcl-2 mRNA, G3139 (oblimersen sodium; Genasense), has been shown to downregulate Bcl-2 and produce responses in a variety of malignancies including drug-resistant lymphoma. Incubation of ex vivo purified plasma cells from patients wit...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402768

    authors: van de Donk NW,Kamphuis MM,van Dijk M,Borst HP,Bloem AC,Lokhorst HM

    更新日期:2003-01-01 00:00:00

  • Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis.

    abstract::Fas ligand (FasL) is capable of inducing apoptosis of lymphoid cells by cross-linking with its natural receptor, Fas. We aimed to investigate the possible role of the Fas/FasL-mediated apoptosis in the development of human lymphomas. FasL mRNA was detected by reverse transcriptase-polymerase chain reaction in 38 out o...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400815

    authors: Xerri L,Devilard E,Hassoun J,Haddad P,Birg F

    更新日期:1997-11-01 00:00:00

  • Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment wi

    abstract::Adhesion molecules and stromal cell-derived factor-1 (SDF-1)/CXCR4 signaling play key role in homing and mobilization of hematopoietic progenitor (HPC) and hematopoietic cancer clonogenic cells (HCC). High expression of VLA-4 is required for homing of HPC and HCC, whereas downregulation of these molecules is required ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2403173

    authors: Gazitt Y

    更新日期:2004-01-01 00:00:00

  • t(12;17)(p13;q21) in early pre-B acute lymphoid leukemia.

    abstract::Structural rearrangements involving the short arm of chromosome 12 occur in 10% of cases of childhood acute lymphoid leukemia. The translocation t(12;17)(p13;q21), an uncommon 12p abnormality, was identified in five of 2620 cases (0.2%) successfully karyotyped by the Pediatric Oncology Group or St Jude Children's Rese...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Krance RA,Raimondi SC,Dubowy R,Estrada J,Borowitz M,Behm F,Land VJ,Pullen J,Carroll AJ

    更新日期:1992-04-01 00:00:00

  • Lack of reciprocal translocation in BCR-ABL positive Ph-negative chronic myeloid leukaemia.

    abstract::We used fluorescence in situ hybridization (FISH) to metaphase chromosomes with BCR and ABL cosmid probes in conjunction with the polymerase chain reaction (PCR) to study the mechanism by which the ABL proto-oncogene is inserted into a morphologically normal chromosome 22 in patients with Ph-negative chronic myeloid l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lazaridou A,Chase A,Melo J,Garicochea B,Diamond J,Goldman J

    更新日期:1994-03-01 00:00:00

  • BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).

    abstract::Modern treatment strategies, consisting of intensive chemotherapy and cranial irradiation, have remarkably improved the prognosis for children with acute lymphoblastic leukemia. However, patients with a potential for cure are at risk of severe acute and late adverse effects of treatment. Furthermore, in 25-30% of pati...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1038/sj.leu.2402489

    authors: Kamps WA,Bökkerink JP,Hakvoort-Cammel FG,Veerman AJ,Weening RS,van Wering ER,van Weerden JF,Hermans J,Slater R,van den Berg E,Kroes WG,van der Does-van den Berg A

    更新日期:2002-06-01 00:00:00

  • Action of interferons in hairy cell leukemia.

    abstract::We have investigated the direct effects of interferon (IFN) on hairy cells (HCs) isolated from patients with hairy cell leukemia using one- and two-dimensional gel electrophoresis. We have previously characterized the induction of synthesis of 10-16 specific proteins by IFN-alpha 2b in HCs, as analyzed by one-dimensio...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Samuels BL,Rosner MC,Giometti CS,Golomb HM,Brownstein BH

    更新日期:1987-04-01 00:00:00

  • CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.

    abstract::Upregulation of the immunosuppressive cell surface glycoprotein, CD200, is a common feature of acute myeloid leukemia (AML) and is associated with poor patient outcome. We investigated whether CD200 overexpression on AML cells could specifically compromise patient natural killer (NK) cell anti-tumor responses. We foun...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.1

    authors: Coles SJ,Wang EC,Man S,Hills RK,Burnett AK,Tonks A,Darley RL

    更新日期:2011-05-01 00:00:00

  • MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

    abstract::MK-0457, an Aurora kinase and BCR-ABL inhibitor, was studied on a Phase I/II study in 77 patients with refractory hematologic malignancies. The average number of cycles per patient was 3 (range 1-21). Maximum tolerated doses for a 5-day short infusion and continuous infusion regimens were 40 mg/m(2)/h and 144 mg/m(2)/...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.186

    authors: Giles FJ,Swords RT,Nagler A,Hochhaus A,Ottmann OG,Rizzieri DA,Talpaz M,Clark J,Watson P,Xiao A,Zhao B,Bergstrom D,Le Coutre PD,Freedman SJ,Cortes JE

    更新日期:2013-01-01 00:00:00

  • Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia.

    abstract::Donor leukocyte infusions (DLI) have turned out to be an efficient way to re-establish complete remission (CR) in chronic myeloid leukemia (CML) patients relapsing after allogeneic bone marrow transplantation (BMT). In these patients, absence of PCR bcr-abl fusion transcripts confirmed the potency of donor leukocytes ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401144

    authors: Berthou C,Léglise MC,Herry A,Balcon D,Hardy E,Lessard M,Abgrall JF

    更新日期:1998-11-01 00:00:00

  • General Report on the European Union Concerted Action Workshop on 11q23, London, UK, May 1997.

    abstract::Seventeen cytogenetic laboratories in eight European countries contributed karyotypic, hematological, clinical and follow-up data from 550 patients with an acquired abnormality of 11q23. The patients had acute lymphoblastic leukemia (254), acute myeloid leukemia (250), unspecified, undifferentiated, biphenotypic acute...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401011

    authors: Secker-Walker LM

    更新日期:1998-05-01 00:00:00

  • The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia.

    abstract::Improved survival of patients with acute lymphoblastic leukemia (ALL) has emerged from identifying new prognostic markers; however, 20% of children still suffer recurrence. Previously, the altered expression of Fat1 cadherin has been implicated in a number of solid tumors. In this report, in vitro analysis shows that ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.319

    authors: de Bock CE,Ardjmand A,Molloy TJ,Bone SM,Johnstone D,Campbell DM,Shipman KL,Yeadon TM,Holst J,Spanevello MD,Nelmes G,Catchpoole DR,Lincz LF,Boyd AW,Burns GF,Thorne RF

    更新日期:2012-05-01 00:00:00

  • High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.

    abstract::Acute myeloid leukemia (AML) is an aggressive malignancy, and development of new treatments to prolong remissions is warranted. Chimeric antigen receptor (CAR) T-cell therapies appear promising but on-target, off-tumor recognition of antigen in healthy tissues remains a concern. Here we isolated a high-affinity (HA) f...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.35

    authors: Lynn RC,Feng Y,Schutsky K,Poussin M,Kalota A,Dimitrov DS,Powell DJ Jr

    更新日期:2016-06-01 00:00:00

  • Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo.

    abstract::P38α/β has been described as a tumor-suppressor controlling cell cycle checkpoints and senescence in epithelial malignancies. However, p38α/β also regulates other cellular processes. Here, we describe a role of p38α/β as a regulator of acute lymphoblastic leukemia (ALL) proliferation and survival in experimental ALL m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.153

    authors: Alsadeq A,Strube S,Krause S,Carlet M,Jeremias I,Vokuhl C,Loges S,Aguirre-Ghiso JA,Trauzold A,Cario G,Stanulla M,Schrappe M,Schewe DM

    更新日期:2015-12-01 00:00:00

  • Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome.

    abstract::We investigated the expression of P-glycoprotein (P-gp) in 52 adults with de novo acute myelogenous leukemia (AML) at the initial diagnosis. We tested 52 patients by flow cytometry using the MRK16 monoclonal antibody (MoAb). To investigate the phenotype for multidrug resistance, 41 of the patients were analyzed using ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Ino T,Miyazaki H,Isogai M,Nomura T,Tsuzuki M,Tsuruo T,Ezaki K,Hirano M

    更新日期:1994-09-01 00:00:00

  • Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

    abstract::Unlike the case with acute myeloid leukemia, there is limited information on the prognostic impact of isocitrate dehydrogenase (IDH) mutations in myelodysplastic syndromes (MDS). In the current study of 277 patients with MDS, IDH mutations were detected in 34 (12%) cases: 26 IDH2 (all R140Q) and 8 IDH1 (6 R132S and 2 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.298

    authors: Patnaik MM,Hanson CA,Hodnefield JM,Lasho TL,Finke CM,Knudson RA,Ketterling RP,Pardanani A,Tefferi A

    更新日期:2012-01-01 00:00:00

  • A model system for leukemic transformation of immortalized hemopoietic cells in irradiated recipient mice.

    abstract::Proliferation in vitro of the murine hemopoietic cell line FDC-P1 is dependent on stimulation by granulocyte-macrophage colony stimulating factor or multipotential colony stimulating factor. Although immortalized, the cells are not tumorigenic on subcutaneous inoculation. Intravenous injection of FDC-P1 cells into syn...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dührsen U,Metcalf D

    更新日期:1988-06-01 00:00:00

  • Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

    abstract::Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during ...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41375-020-0758-4

    authors: Kayser S,Rahmé R,Martínez-Cuadrón D,Ghiaur G,Thomas X,Sobas M,Guerci-Bresler A,Garrido A,Pigneux A,Gil C,Raffoux E,Tormo M,Vey N,de la Serna J,Salamero O,Lengfelder E,Levis MJ,Fenaux P,Sanz MA,Platzbecker U,Schlen

    更新日期:2020-09-01 00:00:00

  • The proteasome: a novel target for cancer chemotherapy.

    abstract::The ubiquitin-proteasome system is an important regulator of cell growth and apoptosis. The potential of specific proteasome inhibitors to act as novel anti-cancer agents is currently under intensive investigation. Several proteasome inhibitors exert anti-tumour activity in vivo and potently induce apoptosis in tumour...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2402417

    authors: Almond JB,Cohen GM

    更新日期:2002-04-01 00:00:00

  • Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.

    abstract::Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally define...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.93

    authors: Callahan KP,Minhajuddin M,Corbett C,Lagadinou ED,Rossi RM,Grose V,Balys MM,Pan L,Jacob S,Frontier A,Grever MR,Lucas DM,Kinghorn AD,Liesveld JL,Becker MW,Jordan CT

    更新日期:2014-10-01 00:00:00

  • Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

    abstract::We evaluated the impact of salvage regimens and allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between 1993 and 2009, 3324 patients with newly diagnosed AML were enrolled in 5 prospective treatment trials of the German-Austrian AML Study Group. After fi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.23

    authors: Wattad M,Weber D,Döhner K,Krauter J,Gaidzik VI,Paschka P,Heuser M,Thol F,Kindler T,Lübbert M,Salih HR,Kündgen A,Horst HA,Brossart P,Götze K,Nachbaur D,Köhne CH,Ringhoffer M,Wulf G,Held G,Salwender H,Benner A,G

    更新日期:2017-06-01 00:00:00

  • Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.

    abstract::Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly conserved long non-coding RNA (lncRNA). Overexpression of MALAT1 has been demonstrated to related to poor prognosis of multiple myeloma (MM) patients. Here, we demonstrated that MALAT1 plays important roles in MM DNA repair and cell death. We ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0104-2

    authors: Hu Y,Lin J,Fang H,Fang J,Li C,Chen W,Liu S,Ondrejka S,Gong Z,Reu F,Maciejewski J,Yi Q,Zhao JJ

    更新日期:2018-10-01 00:00:00

  • Abnormalities of chromosome 16q in myeloid malignancy: 14 new cases and a review of the literature.

    abstract::Fourteen patients with abnormalities of chromosome 16q, 13 with acute myelogenous leukaemia (AML), and one with refractory anaemia with excess of blasts (RAEB), are described. Seven patients had inv(16)(p13q22), two had del(16)(q22), and five had other abnormalities of 16q. Six of the seven patients with inv(16) had A...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Betts DR,Rohatiner AZ,Evans ML,Rassam SM,Lister TA,Gibbons B

    更新日期:1992-12-01 00:00:00

  • NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.

    abstract::Inhibition of NOTCH1 signaling with gamma-secretase inhibitors (GSIs) has been proposed as a molecularly targeted therapy in T-cell acute lymphoblastic leukemia (T-ALL). However, GSIs seem to have limited antileukemic activity in human T-ALL and are associated with severe gastrointestinal toxicity resulting from inhib...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.75

    authors: Real PJ,Ferrando AA

    更新日期:2009-08-01 00:00:00

  • Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells.

    abstract::Transcriptional regulation of the HOXA genes is thought to involve CTCF-mediated chromatin loops and the opposing actions of the COMPASS and Polycomb epigenetic complexes. We investigated the role of these mechanisms at the HOXA cluster in AML cells with the common NPM1c mutation, which express both HOXA and HOXB gene...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0856-3

    authors: Ghasemi R,Struthers H,Wilson ER,Spencer DH

    更新日期:2020-05-12 00:00:00

  • Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

    abstract::This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with c...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2017.327

    authors: Bringhen S,D'Agostino M,De Paoli L,Montefusco V,Liberati AM,Galieni P,Grammatico S,Muccio VE,Esma F,De Angelis C,Musto P,Ballanti S,Offidani M,Petrucci MT,Gaidano G,Corradini P,Palumbo A,Sonneveld P,Boccadoro M

    更新日期:2018-04-01 00:00:00